<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008316</url>
  </required_header>
  <id_info>
    <org_study_id>P170910J</org_study_id>
    <secondary_id>2018-002114-13</secondary_id>
    <nct_id>NCT04008316</nct_id>
  </id_info>
  <brief_title>Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis</brief_title>
  <acronym>COLCHIVAS</acronym>
  <official_title>Evaluation of Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunoglobulin A vasculitis (IgA-V), formerly called Henoch-Schönlein purpura, is an immune&#xD;
      vasculitis. Relapses are frequent (30%) and most of the time cutaneous (90%). Cutaneous&#xD;
      involvement in adults is more severe (haemorrhagic blister or necrotic skin lesions) and more&#xD;
      extensive than in children. Quality of life can be significantly altered by frequent&#xD;
      cutaneous relapses. Colchicine, historically used for gout flares, is known to be an &quot; old &quot;&#xD;
      low cost drug inducing very few adverse events. This molecule inhibits polymorphonuclear&#xD;
      cell-chemotaxis to the site of inflammation explaining colchicine clinical efficacy in&#xD;
      diseases such as Familial Mediterranean Fever or Behçet disease. Efficacy of colchicine has&#xD;
      also been reported in cutaneous leukocytoclastic vasculitis including IgA-V, but without&#xD;
      clinical studies supporting this attitude.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunoglobulin A vasculitis (IgA-V), formerly called Henoch-Schönlein purpura, is an immune&#xD;
      vasculitis. Relapses are frequent (30%) and most of the time cutaneous (90%). Cutaneous&#xD;
      involvement in adults is more severe (haemorrhagic blister or necrotic skin lesions) and more&#xD;
      extensive than in children. Quality of life can be significantly altered by frequent&#xD;
      cutaneous relapses. Colchicine, historically used for gout flares, is known to be an &quot; old &quot;&#xD;
      low cost drug inducing very few adverse events. It inhibits polymorphonuclear cell-chemotaxis&#xD;
      to the site of inflammation explaining colchicine clinical efficacy in diseases such as&#xD;
      Familial Mediterranean Fever or Behçet disease. Efficacy of colchicine has also been reported&#xD;
      in cutaneous leukocytoclastic vasculitis including IgA-V, but without clinical studies&#xD;
      supporting this attitude To assess efficacy of colchicine in adult's cutaneous IgA-V, the&#xD;
      investigators conduct a prospective, controlled, double blind, randomized clinical trial,&#xD;
      national, multicenter and multidisciplinary (internal medicine, nephrology and dermatology):&#xD;
      colchicine 1mg/day versus placebo for 6 months, with a 12 months total follow-up. The primary&#xD;
      objective is to evaluate efficacy of colchicine versus placebo to prevent cutaneous relapses,&#xD;
      6 months after inclusion, in adult patients with cutaneous IgA vasculitis alone or associated&#xD;
      with non-severe digestive or renal involvement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">May 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 12, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective, controlled, double blind, randomized clinical trial: colchicine 1mg/day versus placebo for 6 months, with a 12 months total follow-up.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the occurrence of the first cutaneous skin relapse</measure>
    <time_frame>6 months</time_frame>
    <description>Cutaneous skin relapse is defined by reappearance of palpable purpura with lower limb predominance and not related to thrombocytopenia.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>IgA Vasculitis</condition>
  <arm_group>
    <arm_group_label>colchicine 1mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine per os: 1 tablet (1mg) / day during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 1 tablet / day during 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>colchicine 1mg/day</description>
    <arm_group_label>colchicine 1mg/day</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years and &lt; 85 years&#xD;
&#xD;
          2. IgA-V recently diagnosed (&lt; 20 days since skin biopsy) and defined by :&#xD;
&#xD;
               -  Histologically proven small vessels vasculitis with IgA deposits IgA Vasculitis&#xD;
&#xD;
               -  Purpura and/or involvement of at least one organ among kidney, joint, or&#xD;
                  intestinal tract&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe renal IgA vasculitis:&#xD;
&#xD;
               -  impaired renal function, defined as an eGFR &lt; 60 ml per minute per 1.73 m2 (MDRD&#xD;
                  or CKD-EPI formula)&#xD;
&#xD;
               -  proteinuria/creatinuria&gt; 1g/g&#xD;
&#xD;
               -  Uncontrolled blood pressure (Systolic blood pressure &gt; 170 mmHg, diastolic blood&#xD;
                  pressure &gt; 100 mmHg)&#xD;
&#xD;
          2. Severe digestive IgA vasculitis:&#xD;
&#xD;
               -  intussusception&#xD;
&#xD;
               -  massive gastrointestinal haemorrhage (requiring transfusion)&#xD;
&#xD;
               -  intestinal ischemia&#xD;
&#xD;
               -  perforation&#xD;
&#xD;
               -  abdominal pain persisting more than one day (EVA &gt; 5) and unresponsive to&#xD;
                  standard analgesics (level 1 or 2).&#xD;
&#xD;
          3. Prior (&lt; 3 months) immunosuppressive or corticosteroid therapy&#xD;
&#xD;
          4. Additional cutaneous, and/or digestive and/or chronic renal diseases.&#xD;
&#xD;
          5. HIV and B and C Chronic hepatitis&#xD;
&#xD;
          6. Pregnancy or breast feeding or women without sufficient contraception among women of&#xD;
             childbearing&#xD;
&#xD;
          7. Known allergy or intolerance to study medication or any of its excipients (lactose,&#xD;
             saccharose)&#xD;
&#xD;
          8. Contraindication to colchicine such as:&#xD;
&#xD;
               -  severe hepatic insufficiency&#xD;
&#xD;
               -  combination with a macrolide (except spiramycin),&#xD;
&#xD;
               -  combination with pristinamycin&#xD;
&#xD;
          9. Participation in another interventional trial&#xD;
&#xD;
         10. Patient having not signed an informed consent&#xD;
&#xD;
         11. Patient without Social Security System Insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evangeline PILLEBOUT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evangeline PILLEBOUT, MD</last_name>
    <phone>+33 1 42 49 96 05</phone>
    <email>evangeline.pillebout@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra AUDMARD-VERGER, MD</last_name>
    <phone>+33 2 31 06 45 79</phone>
    <email>alexandra.audemard-verger@chu-caen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangeline PILLEBOUT, MD</last_name>
      <phone>+33 1 42 49 96 053</phone>
      <email>evangeline.pillebout@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra AUDMARD-VERGER, MD</last_name>
      <phone>+33 2 31 06 45 79</phone>
      <email>alexandra.audemard-verger@chu-caen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandra AUDMARD-VERGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

